Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Neuren Pharmaceuticals Limited (NURPF) Stock Price & Analysis

56 Followers

NURPF Stock Chart & Stats

$14.00$0.00(0.00%)
At close: 4:00 PM EST
$14$15$16$17Aug 10Aug 27Sep 2Sep 22Oct 2Nov 3
Day’s Range
$14.00 - $14.00
52-Week Range
$7.70 - $17.61
Previous Close
$14.00
Volume
N/A
Average Volume (3M)
254
Market Cap
$1.74B
Enterprise Value
$1.97B
Total Cash (Recent Filing)
$286.54M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
149.3
Beta
0.53
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
0.2
Last Dividend Ex-Date
Sep 15, 2026
Dividend Yield
0.75%

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

A debt-free balance sheet and substantial cash reserve reduce financial pressure while funding Neuren’s clinical programs internally. This provides flexibility to continue development, absorb execution delays, and avoid near-term reliance on potentially dilutive capital raising.

DAYBUE Royalty Growth

DAYBUE provides an established commercial and royalty base, while upgraded sales guidance indicates continuing product expansion. Higher recurring royalties can support dividends, clinical investment, and milestone-funded growth without requiring Neuren to build a large direct sales organization.

Pipeline And Commercial Optionality

Neuren combines commercial progress from DAYBUE with multiple sources of future optionality, including Koala Phase III, international launches, milestones, and the Priority Review Voucher. Successful execution could broaden revenue beyond current royalties and strengthen long-term strategic flexibility.

Bears Say

Revenue Volatility

The sharp 2025 revenue decline shows that reported growth has not been consistently durable despite strong profitability. Such volatility makes future earnings and royalty-related outcomes harder to forecast and increases dependence on product uptake, milestones, and development progress.

Inconsistent Cash Conversion

Uneven conversion of accounting earnings into cash reduces confidence in the stability of internally generated funding. Although cash generation was strong in other years, recurring negative periods could constrain investment capacity if development spending rises or commercial receipts fluctuate.

Clinical And Regulatory Delays

The HIE delay postpones a key development milestone, while Koala’s placebo-controlled design and two co-primary endpoints create execution and timing risk. Delays or weaker results could defer approvals, milestones, and diversification beyond DAYBUE royalties.

Neuren Pharmaceuticals Limited News

NURPF FAQ

What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?
Neuren Pharmaceuticals Limited lowest stock price was $7.70 and its highest was $17.61 in the past 12 months.
What is Neuren Pharmaceuticals Limited’s market cap?
Neuren Pharmaceuticals Limited’s market cap is $1.74B.
When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?
Neuren Pharmaceuticals Limited’s next earnings report is estimated for Feb 24, 2027 (not yet confirmed), which is in 110 days.
How were Neuren Pharmaceuticals Limited’s earnings last quarter?
Neuren Pharmaceuticals Limited released its earnings results on Aug 25, 2026. The company reported $0.027 earnings per share for the quarter, missing the consensus estimate of $0.062 by -$0.036.
Is Neuren Pharmaceuticals Limited overvalued?
According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued.
Does Neuren Pharmaceuticals Limited pay dividends?
Neuren Pharmaceuticals Limited pays a ― dividend of $0.105 which represents an annual dividend yield of 0.75%. See more information on Neuren Pharmaceuticals Limited dividends here
What is Neuren Pharmaceuticals Limited’s EPS estimate?
Neuren Pharmaceuticals Limited’s EPS estimate is 0.20.
How many shares outstanding does Neuren Pharmaceuticals Limited have?
Neuren Pharmaceuticals Limited has 126,773,980 shares outstanding.
What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?
Neuren Pharmaceuticals Limited reported an EPS of $0.027 in its last earnings report, missing expectations of $0.062. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in NURPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology